NICE issues negative ACD for Piqray for advanced breast cancer patients
The UK health technology assessor the National Institute for Health and Care Excellence on Thursday advised the National Health Service in England to not provide Novartis' (NOVN: VX) Piqray (alpelisib) with fulvestrant to post-menopausal women and men with a certain type of advanced breast cancer.
Even though indirect comparisons suggested that Piqray-based treatment may be more effective than Novartis' Afinitor (everolimus) with exemestane, which is currently the only option for NHS patients at this stage, the committee said it saw no direct evidence in favor of the Piqray-based regimen when comparing it against this standard treatment. The decision is open for public comment until April 21.
Novartis' list price is £4,082.14 ($5,365.18) per 56-pack of 150mg Piqray tablets. The average cost of a course of Piqray-fulvestrant combination treatment has a list price is £6,170.70 for the loading dose and £5,126.42 for subsequent cycles.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze